Intech Biopharm Corporation (TPEX:6461)

Taiwan · Delayed Price · Currency is TWD

16.10

-0.35 (-2.13%)

Jul 9, 2026, 2:31 PM CST

-7.20% (1Y)

Market Cap	2.87B +2.5%
Revenue (ttm)	117.49M +259.6%
Net Income	-412.53M
EPS	-2.56
Shares Out	178.35M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	109,229
Open	16.70
Previous Close	16.45
Day's Range	16.00 - 16.70
52-Week Range	14.10 - 26.25
Beta	0.15
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About Intech Biopharm

Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. The company offers combinations, formulations, and generic drugs for the treatment of respiratory diseases using technology platforms, such as inhaled low ethanol formulation, a metered dose inhaler platform for treating asthma and COPD, as well as dry powder inhaler that comprises blisters and capsules. Its products include SYN006, SYN010, SYN007, Synflutide, Duasma,Synvent, and SYN011. The company was ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2010

Employees 96

Stock Exchange Taipei Exchange

Ticker Symbol 6461

Full Company Profile

Financial Performance

In 2025, Intech Biopharm's revenue was 107.53 million, an increase of 170.31% compared to the previous year's 39.78 million. Losses were -389.03 million, 5.66% more than in 2024.

Financial Statements